title: Why pumps? Continuous subcutaneous insulin infusion for children and adolescents with type 1 diabetes.
abstract: CSII is a feasible, safe and well-accepted mode of therapy for many children with type 1 diabetes. For a significant number of patients and parents, it serves as a much easier means of coping with the huge daily burden of diabetes. Therefore, we believe that both CSII and MDI should be made available to the diabetic team and the patients to better tailor therapy, improve satisfaction and decrease the fear of hypoglycemia.
authors.affiliation: Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tiqva, Israel. nweintrob@clalit.org.il
authors.forename: Naomi
authors.initials: N
authors.lastname: Weintrob
authors.forename: Shlomit
authors.initials: S
authors.lastname: Shalitin
authors.forename: Moshe
authors.initials: M
authors.lastname: Phillip
mesh_terms: D000293:Adolescent; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems / Q000009:adverse effects / Q000523:psychology; D017060:Patient Satisfaction
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin